Syndax Shares Fall 17% After Disappointing Lung Disease Trial Results

Syndax Pharmaceuticals shares fell 17% to $13.80 after the drugmaker reported disappointing trial results for a lung disease treatment, setting back efforts to expand the market for an approved medicine.